A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemia (CP-CML).

Trial Profile

A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemia (CP-CML).

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms OPTIM IMATINIB
  • Most Recent Events

    • 08 Dec 2015 Status changed from recruiting to completed, according to the results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 28 Mar 2012 Planned end date (14 Jun 2013) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top